By reinforcing the concept of a durable, possibly neuroprotective effect, this study strengthened the rationale for GLP-1 RAs as disease-modifying candidates in Parkinsons disease and supported the design of larger randomized trials
As a busy primary care provider with the best intentions of being available to my patients when starting them on a new medication, I typically wouldnt find out about side effects or what prompted them to stop taking the drug until our next visit, months laterand by then, they had already made up their mind that they wanted to try something else
Regulatory and Clinical Support : Guidelines recognizing obesity as a chronic disease and broader approval of GLP1 drugs are pushing adoption and reimbursement in healthcare systems
These variants may help provide context about baseline hormone sensitivity, though they do not predict exact medication response or guarantee outcomes
The evolution of the GPCR signaling system in eukaryotes: modularity, conservation, and the transition to metazoan multicellularity